JP2020529835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529835A5 JP2020529835A5 JP2019571685A JP2019571685A JP2020529835A5 JP 2020529835 A5 JP2020529835 A5 JP 2020529835A5 JP 2019571685 A JP2019571685 A JP 2019571685A JP 2019571685 A JP2019571685 A JP 2019571685A JP 2020529835 A5 JP2020529835 A5 JP 2020529835A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- antigen
- group
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 65
- 108091000831 antigen binding proteins Proteins 0.000 claims description 65
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 50
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 241000701806 Human papillomavirus Species 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 18
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 7
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000012642 immune effector Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 4
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 210000004392 genitalia Anatomy 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 238000007422 luminescence assay Methods 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 201000006958 oropharynx cancer Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 229960002566 papillomavirus vaccine Drugs 0.000 claims description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 11
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004085 squamous epithelial cell Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023206822A JP7737440B2 (ja) | 2017-06-28 | 2023-12-07 | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762525937P | 2017-06-28 | 2017-06-28 | |
| US62/525,937 | 2017-06-28 | ||
| PCT/US2018/039654 WO2019005897A1 (en) | 2017-06-28 | 2018-06-27 | HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023206822A Division JP7737440B2 (ja) | 2017-06-28 | 2023-12-07 | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529835A JP2020529835A (ja) | 2020-10-15 |
| JP2020529835A5 true JP2020529835A5 (https=) | 2021-07-26 |
| JP7401312B2 JP7401312B2 (ja) | 2023-12-19 |
Family
ID=63080480
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571685A Active JP7401312B2 (ja) | 2017-06-28 | 2018-06-27 | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 |
| JP2023206822A Active JP7737440B2 (ja) | 2017-06-28 | 2023-12-07 | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023206822A Active JP7737440B2 (ja) | 2017-06-28 | 2023-12-07 | 抗ヒトパピローマウイルス（ｈｐｖ）抗原結合性タンパク質およびその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10806780B2 (https=) |
| EP (1) | EP3645562A1 (https=) |
| JP (2) | JP7401312B2 (https=) |
| KR (2) | KR102877389B1 (https=) |
| CN (2) | CN118978585A (https=) |
| AU (1) | AU2018290856B2 (https=) |
| BR (1) | BR112019027211A2 (https=) |
| CA (1) | CA3066779A1 (https=) |
| CL (3) | CL2019003802A1 (https=) |
| CO (1) | CO2020000733A2 (https=) |
| EA (1) | EA202090149A1 (https=) |
| IL (3) | IL299348B2 (https=) |
| MA (1) | MA49512A (https=) |
| MX (2) | MX2019015477A (https=) |
| MY (1) | MY200131A (https=) |
| PH (1) | PH12019502763A1 (https=) |
| SG (1) | SG11201912240QA (https=) |
| WO (1) | WO2019005897A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201912240QA (en) * | 2017-06-28 | 2020-01-30 | Regeneron Pharma | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof |
| BR112020006643A2 (pt) | 2017-10-03 | 2020-09-24 | Juno Therapeutics Inc | moléculas de ligação específica ao hpv |
| AU2019249209A1 (en) | 2018-04-05 | 2020-10-15 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
| MA56468A (fr) * | 2019-07-03 | 2022-05-11 | Regeneron Pharma | Protéines de liaison à l'antigène de carcinome 1 à cellules squameuses de l'oesophage anti-new york (ny-eso-1) et leurs procédés d'utilisation |
| BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
| SG11202110145SA (en) | 2020-02-26 | 2021-10-28 | Vir Biotechnology Inc | Antibodies against sars-cov-2 and methods of using the same |
| CN111410689B (zh) * | 2020-03-16 | 2021-11-02 | 重庆理工大学 | 抗hpv16e7蛋白单抗69e2、杂交瘤细胞株及其制备方法和应用 |
| CN111333720B (zh) * | 2020-03-16 | 2021-11-02 | 重庆理工大学 | 抗hpv16e7蛋白单抗79a11、杂交瘤细胞株及其制备方法和应用 |
| CN112433055A (zh) * | 2020-11-04 | 2021-03-02 | 上海药明生物技术有限公司 | 一种基于报告基因方法检测pvrig抗体的生物学活性的方法 |
| CN112480217B (zh) * | 2020-11-30 | 2022-04-08 | 广州阿格纳生物医药制造有限公司 | 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物 |
| CN114957452B (zh) * | 2021-02-18 | 2025-08-08 | 江苏瑞科生物技术股份有限公司 | 一种人乳头瘤病毒11型l1蛋白的抗体及其制备方法 |
| TW202321282A (zh) | 2021-07-19 | 2023-06-01 | 美商再生元醫藥公司 | Il12受體促效劑及其使用方法 |
| TW202322846A (zh) | 2021-08-16 | 2023-06-16 | 美商再生元醫藥公司 | 新穎的il27受體促效劑及其使用方法 |
| WO2023133193A1 (en) * | 2022-01-05 | 2023-07-13 | Memorial Sloan-Kettering Cancer Center | Anti-hpv antibodies and uses thereof |
| US20250188182A1 (en) * | 2022-03-10 | 2025-06-12 | Genexine, Inc. | Triple combination drug dosing therapy for head and neck cancer treatment |
| EP4649088A1 (en) | 2023-01-13 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| IL322890A (en) | 2023-02-28 | 2025-10-01 | Regeneron Pharma | Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen |
| CN118725049A (zh) * | 2024-06-28 | 2024-10-01 | 宁波君健生物科技有限公司 | 自复制mRNA序列及其在制备抗HPV肿瘤药物中的用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| WO1987000201A1 (en) | 1985-07-05 | 1987-01-15 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| EP0378576B1 (en) | 1987-09-11 | 1995-01-18 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
| WO1989005345A1 (en) | 1987-12-11 | 1989-06-15 | Whitehead Institute For Biomedical Research | Genetic modification of endothelial cells |
| JP2917998B2 (ja) | 1988-02-05 | 1999-07-12 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 修飾された肝細胞およびその用途 |
| US5180806A (en) * | 1988-05-16 | 1993-01-19 | The Scripps Research Institute | Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods |
| EP0451550A3 (en) | 1990-03-20 | 1991-11-06 | Behringwerke Aktiengesellschaft | Seroreactive epitopes of human papillomavirus (hpv) 16 proteins |
| CN1067382A (zh) * | 1990-09-26 | 1992-12-30 | 布里斯托尔-迈尔斯斯奎尔公司 | 人类乳头状瘤病毒肽的表达以及在致免疫组合物中的应用 |
| JP3249516B2 (ja) | 1990-10-31 | 2002-01-21 | ソマティクス セラピー コーポレイション | 遺伝子治療のためのレトロウイルスのベクター |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002077012A2 (en) * | 2001-03-23 | 2002-10-03 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Human papilloma virus immunoreative peptides |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| CO5770113A1 (es) * | 2006-04-28 | 2007-06-29 | Fundacion Inst De Inmunologia De Colombia | Peptidos para detectar o inducir la produccion de anticuerpos anti el virus de pailoma humano, anti la proteina l1 o anti peptidos de esta proteina |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| EP2344191A4 (en) | 2008-09-02 | 2013-02-13 | Antigen Express Inc | HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| CN102443060B (zh) * | 2010-10-13 | 2014-04-30 | 上海泽润生物科技有限公司 | 一种抗hpv的抗体、其制备方法和应用 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG193023A1 (en) | 2011-02-11 | 2013-10-30 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| EP2567972A1 (en) * | 2011-09-12 | 2013-03-13 | Adriacell S.p.A. | Antibodies against E7 protein of Human Papilloma Virus (HPV) |
| CN102719402B (zh) * | 2012-07-05 | 2014-05-14 | 时宏珍 | Hla-a0201限制性抗hpv抗原特异性ctl的制备方法 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN110511960B (zh) | 2013-07-15 | 2023-05-23 | 美国卫生和人力服务部 | 抗人乳头瘤病毒16 e6 t细胞受体 |
| EP2883550A1 (en) | 2013-12-12 | 2015-06-17 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Novel promiscuous HPV16-derived T helper epitopes for immunotherapy |
| US11028143B2 (en) * | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| IL290655B2 (en) * | 2014-05-29 | 2024-05-01 | Us Health | Anti-human papillomavirus 16 E7 T-cell chelates |
| WO2016081518A2 (en) | 2014-11-17 | 2016-05-26 | Adicet Bio, Inc. | Engineered gamma delta t-cells |
| CN107847570A (zh) * | 2015-05-08 | 2018-03-27 | 优瑞科生物技术公司 | 靶向hpv16‑e7肽/mhc复合体的构建体及其用途 |
| CN105131113B (zh) | 2015-08-26 | 2019-09-06 | 艾托金生物医药（苏州）有限公司 | 用于宫颈癌检测和分级的单隆抗体及其应用 |
| CN110139873A (zh) | 2016-10-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| SG11201912240QA (en) | 2017-06-28 | 2020-01-30 | Regeneron Pharma | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof |
-
2018
- 2018-06-27 SG SG11201912240QA patent/SG11201912240QA/en unknown
- 2018-06-27 KR KR1020247029312A patent/KR102877389B1/ko active Active
- 2018-06-27 BR BR112019027211-9A patent/BR112019027211A2/pt unknown
- 2018-06-27 WO PCT/US2018/039654 patent/WO2019005897A1/en not_active Ceased
- 2018-06-27 EA EA202090149A patent/EA202090149A1/ru unknown
- 2018-06-27 MX MX2019015477A patent/MX2019015477A/es unknown
- 2018-06-27 US US16/019,703 patent/US10806780B2/en active Active
- 2018-06-27 KR KR1020207002440A patent/KR102702859B1/ko active Active
- 2018-06-27 JP JP2019571685A patent/JP7401312B2/ja active Active
- 2018-06-27 AU AU2018290856A patent/AU2018290856B2/en active Active
- 2018-06-27 IL IL299348A patent/IL299348B2/en unknown
- 2018-06-27 MA MA049512A patent/MA49512A/fr unknown
- 2018-06-27 MY MYPI2019007368A patent/MY200131A/en unknown
- 2018-06-27 IL IL317281A patent/IL317281A/en unknown
- 2018-06-27 CA CA3066779A patent/CA3066779A1/en active Pending
- 2018-06-27 CN CN202410994510.9A patent/CN118978585A/zh active Pending
- 2018-06-27 CN CN201880044309.7A patent/CN110914295B/zh active Active
- 2018-06-27 EP EP18749628.6A patent/EP3645562A1/en active Pending
-
2019
- 2019-12-05 PH PH12019502763A patent/PH12019502763A1/en unknown
- 2019-12-06 IL IL271231A patent/IL271231B2/en unknown
- 2019-12-18 MX MX2024002706A patent/MX2024002706A/es unknown
- 2019-12-20 CL CL2019003802A patent/CL2019003802A1/es unknown
-
2020
- 2020-01-23 CO CONC2020/0000733A patent/CO2020000733A2/es unknown
- 2020-08-13 US US16/992,188 patent/US11559576B2/en active Active
-
2021
- 2021-12-16 CL CL2021003368A patent/CL2021003368A1/es unknown
-
2022
- 2022-12-15 US US18/081,782 patent/US12115216B2/en active Active
-
2023
- 2023-12-07 JP JP2023206822A patent/JP7737440B2/ja active Active
-
2024
- 2024-06-27 CL CL2024001977A patent/CL2024001977A1/es unknown
- 2024-09-11 US US18/830,643 patent/US20250064913A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529835A5 (https=) | ||
| IL299348B1 (en) | Antigen-binding proteins against human papillomavirus and methods of using them | |
| JP7143452B2 (ja) | ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用 | |
| TWI793062B (zh) | Ｄｌｌ３及ｃｄ３抗體構築體 | |
| TWI758558B (zh) | Cd96抗體、其抗原結合片段及醫藥用途 | |
| JP6606505B2 (ja) | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 | |
| JP7202185B2 (ja) | 抗ｃｄ３抗体及び該抗体を含む分子 | |
| JP2020528750A5 (https=) | ||
| AU2018312222A1 (en) | Anti-CD47 antibodies and uses thereof | |
| TW201837174A (zh) | 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子 | |
| TW202144417A (zh) | Ｐｖｒｉｇ結合蛋白及其醫藥用途 | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| TW201932491A (zh) | 抗４－１ｂｂ抗體、其抗原結合片段及其醫藥用途 | |
| CN104662153A (zh) | 针对转运体的抗体及其用途 | |
| AU2020390028B2 (en) | Pharmaceutical composition, preparation method therefor and use thereof | |
| TW202327649A (zh) | Ｐｖｒｉｇ／ｔｉｇｉｔ結合蛋白聯合免疫檢查點抑制劑用於治療癌症 | |
| WO2023040945A1 (zh) | 特异性结合pd-1的蛋白及其医药用途 | |
| CN117858903A (zh) | 一种含抗pvrig/tigit双特异性抗体的药物组合物 | |
| WO2023036281A1 (zh) | 抗cd47抗体及其用途 | |
| WO2023241656A1 (zh) | 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途 | |
| CN120603852A (zh) | 一种fap/cd40结合分子的药物组合物及其医药用途 | |
| US20240384006A1 (en) | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases | |
| TW202300516A (zh) | Ｐｄ—１結合蛋白及其醫藥用途 | |
| TW202313692A (zh) | 抗ｉｌ４ｒ抗體的藥物組成物及其用途 | |
| JPWO2021003357A5 (https=) |